The Oncologist,
This article reports on the efficacy and safety of TLC388 in a second‐line setting for patients with poorly differentiated…
An Open‐Label, Single‐Arm, Two‐Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas
Overview of attention for article published in Oncologist, December 2019
Altmetric Badge
Readers on
- mendeley
- 21 Mendeley